drugset / Trial / NCT06689501

12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults

NCT06689501

RandomizedParallel-groupDouble-blindOther

Summary

This is a single-centre, double-blind, randomised, placebo-controlled, 2-arm, parallel-design trial. This trial will examine the impact of a combined treatment of L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate (otherwise known as the "study product") over 12 weeks on energy intake and expenditure in overweight and obese adults. Approximately 44 participants will be recruited to this trial. Participants will give consent to investigator sites to collect their data. The participants will either be randomised to take the study product or placebo. The main question that this trial aims to answer is: The effect of the study product (L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate) as compared to placebo on mean energy intake via 3 x 24h dietary recalls online at week 4.

Timeline

Start
2024-10-30
Primary completion
2025-06-26
Completion
2025-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified Oral
Subject dihydrocapsiate Unknown Oral
Subject protein yeast hydrolysate Unknown Oral

Indications